www.hqdrug.com
- US Toll free:
- Regular US:
- UK:
- Categories list
-
- Alcoholism
- Alzheimer's And Parkinson's
- Analgesics
- Anti-inflammatories
- Antiallergic
- Antibiotics
- Anticonvulsants
- Antidepressants
- Antifungals
- Antiparasitic
- Antivirals
- Arthritis
- Asthma
- Birth Control
- Cancer
- Cardiovascular Diseases
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Care
- Gastrointestinal Tract
- HIV
- Hypertension
- Men's Health
- Mental Disorders
- Migraine
- Muscle Relaxants
- Neurological Disorders
- Obesity
- Osteoporosis
- Respiratory Tract
- Skin Care
- Surgery
- Urinary Tract
- Women's Health
Generic Amantadine - Symmetrel
Generic Symmetrel
Generic Symmetrel is an antiviral. It is used to prevent or treat certain influenza (flu) infections (type A). It may be given alone or along with flu shots. Generic Symmetrel will not work for colds, other types of flu or other virus infections. This medicine is also used to treat Parkinson's disease and other movement disorders.
£ 0.70
Buy now!
Country, language and currency
- Testimonials
-
The parcel has arrived today, thanks for your prompt delivery. The extra pack enclosed to the order is greatly appreciated. - Best regards, U Geilert
Read more »
-
- Michael J. Fox Foundation-Funded Study Identifies Best Dyskinesia Clinical ... - MarketWatch (press release)
- Michael J
- Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA ... - MarketWatch (press release)
- Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA
- Sunnyview Rehabilitation Hospital played role in newly published brain injury ... - Albany Business Review
- Sunnyview Rehabilitation Hospital played role in newly published brain injury
- Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA ... - Moneylife Personal Finance site and magazine
- Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA
- Newron Reports Completion of Phase III program for Safinamide in early and ... - PipelineReview.com (press release)
- Newron Reports Completion of Phase III program for Safinamide in early and
 |
Bookmark this site |
|---|
 |
Subscribe to the News |
|---|
